Evidence map›Paper›PMID 33672048›Full record

ArticleBiomolecules2021

Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease.

Jianshe Wei, Yoshiki Takamatsu, Ryoko Wada, Masayo Fujita, Gilbert Ho, Eliezer Masliah, Makoto Hashimoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Therapeutic Potential ofParkinson's disease · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianshe WeiTokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan.
Yoshiki TakamatsuTokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan.
Ryoko WadaTokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan.
Masayo FujitaTokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan.
Gilbert HoPCND Neuroscience Research Institute, Poway, CA 92064, USA.
Eliezer MasliahDivision of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.
Makoto HashimotoTokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan.ORCID 0000-0003-4626-950X

Funding

Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging populationZIAAG000936 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2017 to 2025
$4.1M
6 · The paper itself

Abstract

Gaucher disease (GD), the most common lysosomal storage disorder (LSD), is caused by autosomal recessive mutations of the glucocerebrosidase gene,

Indexed as

alpha-SynucleinAmyloidAutophagybeta-SynucleinBrainGaucher DiseaseGlucosylceramidaseHumansIntracellular Signaling Peptides and ProteinsLysosomesModels, BiologicalMutationNiemann-Pick C1 ProteinParkinson DiseaseReactive Oxygen SpeciesRiskalpha-SynucleinAmyloidbeta-SynucleinGlucosylceramidaseIntracellular Signaling Peptides and ProteinsNiemann-Pick C1 ProteinNPC1 protein, humanReactive Oxygen SpeciesSNCA protein, humanSNCB protein, humanantagonistic pleiotropyautosomal recessiveevolvabilityGaucher disease (GD)Parkinson’s disease (PD)α-synuclein (αS)β-synuclein (βS)

Identifiers

PMID33672048
PMCPMC7919466

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.